BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 33346915)

  • 21. Multidimensional Analyses of Tumor Immune Microenvironment Reveal the Possible Rationality of Immunotherapy and Identify High Immunotherapy Response Subtypes for Renal Papillary Cell Carcinoma.
    Wei B; Yu M; Yao J; Jiang M; An J; Yang J; Lin J; Zhao Y; Zhu Y
    Front Immunol; 2021; 12():657951. PubMed ID: 34531849
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Low expression of ferritinophagy-related NCOA4 gene in relation to unfavorable outcome and defective immune cells infiltration in clear cell renal carcinoma.
    Mou Y; Wu J; Zhang Y; Abdihamid O; Duan C; Li B
    BMC Cancer; 2021 Jan; 21(1):18. PubMed ID: 33402128
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High-dimensional Cytometry (ExCYT) and Mass Spectrometry of Myeloid Infiltrate in Clinically Localized Clear Cell Renal Cell Carcinoma Identifies Novel Potential Myeloid Targets for Immunotherapy.
    Theodros D; Murter BM; Sidhom JW; Nirschl TR; Clark DJ; Chen L; Tam AJ; Blosser RL; Schwen ZR; Johnson MH; Pierorazio PM; Zhang H; Ganguly S; Pardoll DM; Zarif JC
    Mol Cell Proteomics; 2020 Nov; 19(11):1850-1859. PubMed ID: 32737216
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic value of infiltrating immune cells in clear cell renal cell carcinoma (ccRCC).
    Liu S; Li S; Wang Y; Wang F; Zhang L; Xian S; Yang D; Yuan M; Dai F; Zhao X; Liu Y; Jin Y; Zeng Z; Mahgoub OKA; Zhou C; Cheng Y
    J Cell Biochem; 2020 Mar; 121(3):2571-2581. PubMed ID: 31823423
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immune classification of clear cell renal cell carcinoma.
    Su S; Akbarinejad S; Shahriyari L
    Sci Rep; 2021 Feb; 11(1):4338. PubMed ID: 33619294
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Regulatory T lymphocyte infiltration in metastatic breast cancer-an independent prognostic factor that changes with tumor progression.
    Stenström J; Hedenfalk I; Hagerling C
    Breast Cancer Res; 2021 Feb; 23(1):27. PubMed ID: 33602289
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A novel prognostic model based on immunogenomics for clear cell renal cell carcinoma.
    Wu Z; Shen Y; Fan D; Liu J; Chen D; Wang K; Xu X
    Int Immunopharmacol; 2021 Jan; 90():107119. PubMed ID: 33243605
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Quantitative Analysis of Immune Infiltrates in Primary Melanoma.
    Gartrell RD; Marks DK; Hart TD; Li G; Davari DR; Wu A; Blake Z; Lu Y; Askin KN; Monod A; Esancy CL; Stack EC; Jia DT; Armenta PM; Fu Y; Izaki D; Taback B; Rabadan R; Kaufman HL; Drake CG; Horst BA; Saenger YM
    Cancer Immunol Res; 2018 Apr; 6(4):481-493. PubMed ID: 29467127
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Spatial immunoprofiling of the intratumoral and peritumoral tissue of renal cell carcinoma patients.
    Brück O; Lee MH; Turkki R; Uski I; Penttilä P; Paavolainen L; Kovanen P; Järvinen P; Bono P; Pellinen T; Mustjoki S; Kreutzman A
    Mod Pathol; 2021 Dec; 34(12):2229-2241. PubMed ID: 34215851
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Development and validation of an immune prognostic classifier for clear cell renal cell carcinoma.
    Gu YY; Chen G; Lin P; Cheng JW; Huang ZG; Luo J; Zhai GQ; Wang YL; Yan HB; Li SH
    Cancer Biomark; 2020; 27(2):265-275. PubMed ID: 31929144
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tumor microenvironment immune subtypes for classification of novel clear cell renal cell carcinoma profiles with prognostic and therapeutic implications.
    Wang Q; Hu J; Kang W; Wang J; Xiang Y; Fu M; Gao H; Huang Z
    Medicine (Baltimore); 2021 Mar; 100(11):e24949. PubMed ID: 33725966
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Construction of a Novel Immune-Related lncRNA Pair Signature with Prognostic Significance for Kidney Clear Cell Renal Cell Carcinoma.
    Sun JX; Xia QD; Liu CQ; Xu JZ; Xun Y; Lu JL; Hu J; Wang SG
    Dis Markers; 2021; 2021():8800358. PubMed ID: 34512816
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Spatial heterogeneity of tumor microenvironment influences the prognosis of clear cell renal cell carcinoma.
    Zhang D; Ni Y; Wang Y; Feng J; Zhuang N; Li J; Liu L; Shen W; Zheng J; Zheng W; Qian C; Shan J; Zhou Z
    J Transl Med; 2023 Jul; 21(1):489. PubMed ID: 37474942
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inflammatory cell infiltrates in advanced metastatic uveal melanoma.
    Krishna Y; McCarthy C; Kalirai H; Coupland SE
    Hum Pathol; 2017 Aug; 66():159-166. PubMed ID: 28655639
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Increased intratumoral FOXP3-positive regulatory immune cells during interleukin-2 treatment in metastatic renal cell carcinoma.
    Jensen HK; Donskov F; Nordsmark M; Marcussen N; von der Maase H
    Clin Cancer Res; 2009 Feb; 15(3):1052-8. PubMed ID: 19188179
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma.
    Bi K; He MX; Bakouny Z; Kanodia A; Napolitano S; Wu J; Grimaldi G; Braun DA; Cuoco MS; Mayorga A; DelloStritto L; Bouchard G; Steinharter J; Tewari AK; Vokes NI; Shannon E; Sun M; Park J; Chang SL; McGregor BA; Haq R; Denize T; Signoretti S; Guerriero JL; Vigneau S; Rozenblatt-Rosen O; Rotem A; Regev A; Choueiri TK; Van Allen EM
    Cancer Cell; 2021 May; 39(5):649-661.e5. PubMed ID: 33711272
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Characterizing parathyroid carcinomas and atypical neoplasms based on the expression of programmed death-ligand 1 expression and the presence of tumor-infiltrating lymphocytes and macrophages.
    Silva-Figueroa A; Villalobos P; Williams MD; Bassett RL; Clarke CN; Lee JE; Busaidy NL; Perrier ND
    Surgery; 2018 Nov; 164(5):960-964. PubMed ID: 30033186
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tumor Microenvironment Dynamics in Clear-Cell Renal Cell Carcinoma.
    Vuong L; Kotecha RR; Voss MH; Hakimi AA
    Cancer Discov; 2019 Oct; 9(10):1349-1357. PubMed ID: 31527133
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Integrative -omics and HLA-ligandomics analysis to identify novel drug targets for ccRCC immunotherapy.
    Reustle A; Di Marco M; Meyerhoff C; Nelde A; Walz JS; Winter S; Kandabarau S; Büttner F; Haag M; Backert L; Kowalewski DJ; Rausch S; Hennenlotter J; Stühler V; Scharpf M; Fend F; Stenzl A; Rammensee HG; Bedke J; Stevanović S; Schwab M; Schaeffeler E
    Genome Med; 2020 Mar; 12(1):32. PubMed ID: 32228647
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Geospatial characterization of immune cell distributions and dynamics across the microenvironment in clear cell renal cell carcinoma.
    Chakiryan NH; Kim Y; Berglund A; Chang A; Kimmel GJ; Hajiran A; Nguyen J; Moran-Segura C; Saeed-Vafa D; Katende EN; Lopez-Blanco N; Chahoud J; Rappold P; Spiess PE; Fournier M; Jeong D; Wang L; Teer JK; Dhillon J; Kuo F; Hakimi AA; Altrock PM; Mulé JJ; Manley BJ
    J Immunother Cancer; 2023 Apr; 11(4):. PubMed ID: 37185232
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.